Research
Hormonal
SGLT2 inhibitors are preferred over GLP1RAs for adults with type 2 diabetes and heart failure to reduce major adverse cardiovascular events and worsening heart failure, while GLP1RAs are preferred for chronic kidney disease if SGLT2is are not tolerated.
If you have type 2 diabetes and heart failure, ask about SGLT2 inhibitors (like empagliflozin or dapagliflozin), as they are proven to help your heart. If you have kidney disease, SGLT2 inhibitors are also preferred, but if you can't take them, GLP-1 agonists (like dulaglutide) are a good alternative for protecting your kidneys. Your doctor will choose based on your specific organ risks.
StrongSupportsVERY_HIGH confidence
Accordingly, in people with heart failure, an SGLT2i with known benefit should be started to reduce the risk of major adverse cardiovascular events and worsening heart failure. If SGLT2is are not tolerated or cannot be used, GLP1RAs with demonstrated renal benefit are a reasonable alternative.
Why this rating
Based on dedicated kidney outcome trials and consistent CVOT data for heart failure.
Source
Advances in the management of type 2 diabetes in adults
Rodolfo J. Galindo et al. · BMJ Medicine · 2023
narrative_reviewCited 67×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →